Vical Incorporated (VICL), Bristol Myers Squibb Co. (BMY): This Biotech Stock Might Boost Your Portfolio

There are many promising biotech companies out there to choose from. One such company, named Vical Incorporated (NASDAQ:VICL), is targeting a cancer known as Melanoma. Melanoma is the most dangerous form of skin cancer, and is the leading cause of death for skin disease. The company has a good pipeline, but its lead candidate is Allovectin.

Vical Incorporated

Allovectin approaching results

Results from a phase 3 trial are approaching for Allovectin. Allovectin is a DNA-based immunotherapy designed to stimulate an immune response in tumors. Allovectin will be used as a first-line treatment for patients suffering from stage 3 and stage 4 Melanoma.

What Vical Incorporated (NASDAQ:VICL) hopes to accomplish as a first-line treatment, is that this vaccine has an improved safety profile over toxic chemotherapy. It is also hopeful that the phase 3 trial will show greater efficacy for patients who suffer from Melanoma against current standard of care treatment.

As mentioned before, Allovectin is in phase 3 efficacy trial, and results are set to be out by mid-2013. At that time we will see more in depth results, and whether the efficacy is greater than that of the current chemotherapy treatments. I feel that Allovectin will prove that vaccines can fight cancer, and that the technology is worth pursuing.

The phase 2 trial had enrolled 127 Chemo intolerant patients. The  phase 2 study was done as a single arm study, and it was open label. Vical Incorporated (NASDAQ:VICL) proved the safety of the vaccine,because once the study was completed, there were no severe Grade 3 or Grade 4 adverse events. The overall response rate was great at 11.8%! There were four complete responders in the study, and the other eleven patients were partial responders.

The phase 3 trial is almost complete for Allovectin. Soon, investors and the science community will know whether the vaccine works against late stage melanoma or not. The phase 3 trial began in 2007, and had enrolled a total of 390 patients. Enrollment was completed in 2010, and sometime in 2013, Vical Incorporated (NASDAQ:VICL) will post the results that everyone has been waiting for. The trial had 260 patients take the treatment of Allovectin, while another 130 took standard of care placebo drug alone.

Allovectin, if it proves to be successful, stands to make the company $500 million in sales. The good part about Vical Incorporated (NASDAQ:VICL)’s technology targeting tumors with DNA is that it was also shown to be effective in other tumors. Other indications that can be targeted with Allovectin are: Breast cancer, prostate cancer, head cancer, and neck cancer. With these other indications, Allovectin can become a multi-billion dollar vaccine for the company.

Yervoy in competition mode

There is another biotech company that already has an FDA-approved treatment for melanoma patients. This other biotech company is none other than Bristol Myers Squibb Co. (NYSE:BMY). Their drug, Yervoy, was approved by the FDA on March 25, 2011. On June 6, 2011 Bristol Myers Squibb Co. (NYSE:BMY) reported results of their phase 3 trial of Yervoy. Final results showed that patients taking Yervoy prolonged their lives as opposed to those taking placebo only.

More importantly, Yervoy’s one year survival rate was 46% versus 25% in the control arm. In the second year, the survival rate Yervoy achieved was 24%, compared to only 14% in the control arm. Also, Yervoy saw more survivors in the 3 and 4 year marks than those patients who just took placebo only.

Why Bristol Myers Squibb Co. (NYSE:BMY) should be worried about Vical’s Allovectin is due to its efficacy and safety. If Allovectin comes out with better survival rates and is safer to use than Yervoy, then Bristol-Myers will face stiff competition. That’s the downside to Yervoy, as it has an efficacy situation and safety problems.

The problem with the efficacy is that once the patients receive the doses of Yervoy, it can take weeks for the immune system to start working against the cancer. Thus, the drug doesn’t help all patients in regard to their late stage metastatic melanoma. So, if Allovectin proves efficacy at a quicker stage, it can overtake Yervoy in this regard.

In terms of safety profile, I described above that Allovectin has no grade 3 or grade 4 adverse events. The problem with Yervoy is that there are mild adverse events. Bristol Myers Squibb Co. (NYSE:BMY) attributes these adverse events due T-cell activation and proliferation. So, Allovectin can gain an upper hand against Yervoy, considering it is also safer to use.

GlaxoSmithKline plc (ADR) (NYSE:GSK) joins the party

Well, GlaxoSmithKline plc (ADR) (NYSE:GSK) doesn’t want to let others lead over it in the melanoma market, as it has applied for FDA approval for both dabrafenib and trametinib. The company has also filed for dabrafenib in the EMA, and hopes to also add trametinib in the coming months.

In June 2012, 80% of patients with melanoma who took trametinib were alive at 6 months. That compared to only 67% of the patients alive at 6 months that took Chemotherapy alone.

In terms of dabrafenib, it had delayed disease progression of melanoma patients by 5.1 months. This compares better than patients on chemotherapy alone, which delayed disease progression by only 2.7 months.

Final thoughts

The space for the melanoma market is heating up, and I think that Vical can deliver on their phase 3 results of Allovectin. It will have to produce better results than big pharma companies like Bristol Myers Squibb Co. (NYSE:BMY), and GlaxoSmithKline. The good part about Vical is that their pipeline is pretty extensive.They are also targeting herpes simplex virus and the cytomegalovirus. The company uses its DNA vaccine technology to produce an assortment of vaccines against cancers and infectious diseases.

You can’t go wrong with this speculative play in your portfolio. Also, the success of Allovectin will prove that DNA vaccines are coming of age in the immunotherapy sector. This will show the science community that DNA vaccines can be used as a safe alternative to fight cancers and infectious diseases. So if all goes well, Vical can boost your portfolio.

The article This Biotech Stock Might Boost Your Portfolio originally appeared on Fool.com and is written by Terry Chrisomalis.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!